Abbott Labs Glaukos: Which Stock Is Best to Buy in 2026
In 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
Fundamental analysis is key to maximizing stock returns. By evaluating financial health, you can make informed investment choices that lead to higher profits.
22,179 articlesIn 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
Two iconic retail names clash in a changing market. This analysis breaks down what makes Academy Sports and Tractor S...
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Affluent homeowners are shaping the remodeling outlook as 2026 approaches. Aging housing stock and increased equity b...
A surge in exports, a stronger currency, and deep reform push lift a frontier market into fresh highs. The world’s ho...
Lemonade posted first positive GAAP free cash flow in the latest quarter, a milestone that reshapes the insurtech nar...
CrowdStrike holds steady Wednesday in early trading after strong quarterly results, while GitLab slides on a dimmer g...
Peter Thiel's hedge fund sold Nvidia shares and shifted into Microsoft and Apple, signaling a strategic pivot in AI b...
SanDisk shares jumped about 6% on Friday as a persistent NAND shortage supports higher prices and prolonged demand fr...
Analysts see SpaceX, OpenAI, and Anthropic pursuing record mega-IPOs in 2026, potentially reshaping liquidity for ven...
As Lumentum and Coherent rally, Onto Innovation could be the next optics supplier to gain. Analysts say the surge ref...
Amazon launches a $200 billion AI-focused capex plan for 2026, with Trainium and Anthropic in the mix. Here’s what in...